Clinical Trials Logo

Clinical Trial Summary

This nationwide multicenter prospective cohort study will collect the treatment information and outcomes of the patients with previously untreated cavernous malformations (U-CMs) in China (at least 2000 patients from 20 centers). The investigators aim to determine the effect of different treatments on long-term outcomes in patients with untreated cerebral cavernous malformations.


Clinical Trial Description

Despite the availability of microsurgical excision and stereotactic radiosurgery for cavernoma treatment and known genetic causes of most familial forms of cavernoma, uncertainties remain about cause, diagnosis, prognosis, treatment, and care. According to the recently published CM treatment guideline, surgical and conservative treatments are both first-line therapeutic options in previously untreated CMs (U-CMs). However, given current data, neurosurgeons are still unable to counsel patients on which would be the best option. To address the absence of high level evidence to support cerebral CM treatment decisions, there is a need for a large sample size study of cerebral CM treatment with a prospective concurrent group. China has the largest population in the world and may have the most extensive and valuable clinical resources of U-CMs. But, till now, the current treatment and outcome situation of the disease in China is not well known. Thus, the investigators are conducting a nationwide multicenter prospective registry study in China to determine the effect of different treatments on long-term outcomes in patients with untreated cerebral cavernous malformations.At least 2000 patients with untreated cerebral cavernous malformation will be enrolled from 20 Grade Ⅲ A level hospitals distributed all over China. Clinical data and laboratory data are prospectively collected by electric case report form (CRF) and uploaded online by each neurosurgery center to form the prospective clinical database in First Affiliated Hospital of Fujian Medical University. This is a cohort follow-up study across a 5-year period with a 2 years interval of enrollment and 3 years follow up for each patient. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03467295
Study type Observational
Source First Affiliated Hospital of Fujian Medical University
Contact Fuxin Lin, MD
Phone 13552358381
Email lfxstudy@126.com
Status Recruiting
Phase
Start date January 1, 2018
Completion date March 31, 2023

See also
  Status Clinical Trial Phase
Terminated NCT01764451 - Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins Early Phase 1
Terminated NCT03474614 - Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation Phase 2
Recruiting NCT01764529 - Modifiers of Disease Severity in Cerebral Cavernous Malformations